
EA – previously submitted to ASCO and EHA 2021.
The research was funded by: Acerta Pharm, a member of the
AstraZeneca Group
Keywords: Aggressive B‐cell non‐Hodgkin lymphoma, Molecular
Targeted Therapies, Ongoing Trials
Conflicts of interests pertinent to the abstract
L. H. Sehn
Consultant or advisory role: Celgene, AbbVie, Seattle Genetics, TG
Therapeutics, Janssen, Amgen, Roche/Genentech, Gilead Sciences,
Lundbeck, Amgen, Apobiologix, Karyopharm Therapeutics, Kite
Pharma, Merck, Takeda, Teva, AstraZeneca, Acerta Pharma, Mor-
phosys, Incyte, Debiopharm Group, Sandoz‐Novartis, Genmab,
Verastem
Honoraria: Amgen, Apobiologix, AbbVie, Celgene, Gilead Sciences,
Janssen‐Ortho, Karyopharm Therapeutics, Kite Pharma, Lundbeck,
Merck, Roche/Genentech, Seattle Genetics, Takeda, Teva, TG Ther-
apeutics, AstraZeneca, Acerta Pharma, Morphosys, Incyte, Debio-
pharm Group, Sandoz‐Novartis, Verastem, Genmab, AstraZeneca
Research funding: Roche/Genentech, Teva
B. Kahl
Consultant or advisory role: Celgene, AbbVie, Pharmacyclics, Acerta
Pharma, ADC Therapeutics, Genentech, Roche, BeiGene, Bayer, MEI
Pharma, Kite/Gilead, MorphoSys, Janssen, Karyopharm Therapeutics,
Teva, BMS, Molecular Templates, Incyte
Research funding: Genentech, Acerta Pharma, ADC Therapeutics,
Celgene
Educational grants: Celgene, Juno Therapeutics, Genentech/Roche,
AbbVie, Millenium, Seattle Genetics
M. Matasar
Consultant or advisory role: Genentech, Bayer, Merck, Juno Thera-
peutics, Roche, Teva, Rocket Medical, Seattle Genetics, Daiichi San-
kyo, Takeda;
Stock ownership: Merck
Honoraria: Genentech, Roche, Glaxosmithkline, Bayer, Pharmacy-
clics, Janssen, Seattle Genetics, Immunovaccine Technologies, Takeda
Research funding: Genentech, Roche, Glaxosmithkline, IGM Bio-
sciences, Bayer, Pharmacyclis, Janssen, Rocket Medical, Seattle GE-
netics, Immunovaccine Tech
Educational grants: Genentech, Roche, Seattle Genetics, Bayer
Other remuneration: Expert Testimony: Bayer
G. Lentz
Consultant or advisory role: Roche/Genentech, Janssen‐Cilag,
Bristol‐Myers Squibb, Bayer, Novartis, Celgene, MorphoSys, Astra-
Zeneca, Gilead Sciences
Honoraria: Janssen‐Cilag, Bayer, Celgene, Roche/Genentech, Astra-
Zeneca, BMS, MorphoSys, Gilead Sciences, Novartis, AbbVie
Research funding: Janssen‐Cilag, Roche/Genentech, AstraZeneca,
Aquinox Pharmaceuticals, Bayer, MorphoSys, Gilead Sciences, Vera-
stem, AGIOS
Educational grants: Janssen‐Cilag, Celegene, AstraZeneca, Roche/
Genentech,
Other remuneration: Expert Testimony: MorphoSys
K. Izutsu
Consultant or advisory role: Bayer, Celgene, AstraZeneca, Ono
Pharmaceutical, Kyowa Kirin
Honoraria: Takeda, Chugai Pharma, Eisai, Janssen, AbbVie, Novartis,
MSD, Sumitomo Dainippon Pharma, Ono Pharmaceutical, Mundi-
pharma, HUYA Bioscience International, AstraZeneca, Bayer, BMS,
Kyowa Kirin, Fujifilm, Celgene, Daiichi Sankyo, Allergan
Research funding: Eisai, Chugai Pharma
L. Tao
Employment or leadership position: AstraZeneca
R. Calvo
Employment or leadership position: AstraZeneca
Stock ownership: AstraZeneca
P. L. Zinzani
Consultant or advisory role: Verastem, Celltrion, Gilead, Janseen‐
Cilag, BMS, Servier, Sandoz, MSD, TG Therapeutics, Takeda, Roche,
Eusapharma, Kwoya Kirin, Sanofi, ADC Therapteutics
Other remuneration: Speakers’ Bureau ‐Verastem, Celltrion, Gilead,
Janseen‐Cilag, BMS, Servier, MSD, TG Therapeutics, Takeda, Roche,
Eusapharma, Kyowa Kirin
253 |A PHASE III TRIAL OF GLOFITAMAB PLUS GEMCITABINE
AND OXALIPLATIN (GEMOX) VS RITUXIMAB PLUS GEMOX FOR
RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
M. Hertzberg
1
, M. Ku
2
, O. Catalani
3
, B. Althaus
4
, S. Simko
4
, G. P.
Gregory
5
1
Prince of Wales Hospital, Department of Hematology, Sydney, Australia,
2
St.Vincent's Hospital, The University of Melbourne, Department of
Haematology, Melbourne, Australia,
3
F. Hoffmann‐La Roche Ltd, Statis-
tics, Basel, Switzerland,
4
Genentech, Inc., Product Development Hema-
tology, South San Francisco, USA,
5
School of Clinical Sciences at Monash
Health, Monash University, Department of Clinical Haematology, Mel-
bourne, Australia
Introduction: Prognosis is poor for patients with relapsed/refractory
(R/R) diffuse large B‐cell lymphoma (DLBCL), particularly those who
are ineligible for autologous stem cell transplant (ASCT) or who
relapse after second‐line therapy (Gisselbrecht C, et al. Br J Hae-
matol 2018). While chimeric antigen receptor therapies have shown
favorable response rates in R/R DLBCL, convenient off‐the‐shelf
options are needed, especially for patients with rapidly progressing
disease (Sermer D, et al. Blood Adv 2020). Glofitamab is a full‐length,
humanized immunoglobulin G1 bispecific antibody with two regions
that bind to CD20 (B cells) and one region that binds to CD3 (T cells).
In an ongoing Phase I study in patients with R/R non‐Hodgkin
344
-
SUPPLEMENT ABSTRACTS